Journal of infection and public health · 2026
Incidence, risk factors and causality assessment for colistin-induced acute kidney injury among hospitalized patients in the State of Qatar: A multicenter retrospective study.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Akasheh Duha Samer, Abu Asfour Nour Abdallah, Elajez Reem, Mohammad Mohammad Zeyad, Chaponda Masautso, Mohamed Asmaa Ezzeldin Mohd, Abubakar Usman
Аннотация
OBJECTIVE: To evaluate the incidence, causality and risk factors associated with colistin-induced acute kidney injury (AKI) using the Risk Injury Failure, Loss and End-stage renal disease (RIFLE) criteria.
METHODS: This is a retrospective cohort study that involved patients treated with intravenous colistin from 2016 to 2023 in the State of Qatar. The Naranjo Scale was used for causality assessment.
RESULTS: A total of 186 cases were included in this analysis. The incidence of colistin-induced AKI at day 14 was 23.7%. The median (interquartile range) time to AKI onset was 5.0 (7.0) days. Of the patients with AKI, 6 (12.8%) patients received renal replacement therapy within 30 days. Naranjo causality assessment showed that the majority of the cases (80.9%) had "possible" colistin-induced AKI (score 1 - 4). Colistin dose per administration (adjusted odds ratio [AOR]: 2.286, 95% CI: 1.246 - 4.194, p = 0.008), and sepsis/septic shock (AOR: 2.380, 95% CI: 1.005 - 5.635, p = 0.049) were independent risk factors for colistin-induced AKI.
CONCLUSION: One in four patients receiving colistin develops AKI, and a subset required a renal replacement therapy within 30 days. Close monitoring of patients, and the application of precision medicine are recommended to minimize the risk of AKI.
METHODS: This is a retrospective cohort study that involved patients treated with intravenous colistin from 2016 to 2023 in the State of Qatar. The Naranjo Scale was used for causality assessment.
RESULTS: A total of 186 cases were included in this analysis. The incidence of colistin-induced AKI at day 14 was 23.7%. The median (interquartile range) time to AKI onset was 5.0 (7.0) days. Of the patients with AKI, 6 (12.8%) patients received renal replacement therapy within 30 days. Naranjo causality assessment showed that the majority of the cases (80.9%) had "possible" colistin-induced AKI (score 1 - 4). Colistin dose per administration (adjusted odds ratio [AOR]: 2.286, 95% CI: 1.246 - 4.194, p = 0.008), and sepsis/septic shock (AOR: 2.380, 95% CI: 1.005 - 5.635, p = 0.049) were independent risk factors for colistin-induced AKI.
CONCLUSION: One in four patients receiving colistin develops AKI, and a subset required a renal replacement therapy within 30 days. Close monitoring of patients, and the application of precision medicine are recommended to minimize the risk of AKI.